Registration Info

This is a 1-day meeting and will provide 6 CE/CME credits.

Conference Registration Fee

Practicing Healthcare Professionals: $129

Non-Clinicians / Medical Office Support Staff / Industry Participants

Non-clinicians--including, but not limited to, office managers, billing specialists, receptionists, and administrative staff--may attend PAINWeekEnd on a space-available basis when accompanied by a clinician and will be put on a wait list. These non-clinicians must still pre-register. Participation in industry sponsored meal programs, however, is strictly limited to practicing licensed healthcare providers. Please make necessary arrangements for meals for office support staff. In order to maintain the professional nature of the conference, guests, spouses, friends, and/or family members who are not currently employed in the medical field may not attend PAINWeekEnd.


Unfortunately, we do not have discounts available on hotel rooms. Please contact the hotel directly should you require accommodations.

Santa Clara Marriott
2700 Mission College Blvd.
Santa Clara, CA 95054


To accompany and enrich your experience at the PAINWeekEnd conference, be sure to attend one or more of the sponsored programs, which are scheduled during breakfast, lunch, and afternoon "Brain Food" time slots in the schedule. There is NO ADDITIONAL CHARGE to attend these program sessions!


Click on the day of the conference to see course descriptions, UAN numbers, and AANP pharmacology credits.

Saturday, June 2, 2018

Schedule (subject to change)

7:00a - 7:30a - Registration and Exhibits
Coffee will be served. 

7:30a - 8:30a - Crisis=Opportunity: Reducing Medication Burden While Managing Chronic Pain

UAN 0530-0000-18-060-L01-P

AANP Rx Hours 0.60

Course Description

Although long regarded as an appropriate standard of care for treating acute and cancer pain, the use of prescription opioids to treat chronic benign pain conditions has been highly controversial. The lack of empirical support in conjunction with the increased prevalence of prescription opioid abuse has subsequently led professional and regulatory boards, as well as the general public, to become more critical of physician prescribing practices. As a result, patients who were once prescribed high doses of opioid medication are now being told that they need to reduce or eliminate their reliance on this form of treatment. How can individuals successfully eliminate use of a substance that they have relied on for an extended period of time? A pain physician will review current literature related to the use of opioids and will discuss the medical challenges associated with weaning individuals off of this class of drug. A psychologist will then speak about the role of interdisciplinary treatment programs in facilitating opioid cessation while concurrently improving patients' functional outcomes. Emphasis will be placed on the critical role that psychological and behavioral interventions play in this process, and the evidence which supports their inclusion.

Jennifer M. Hah, MD, MS

8:30a - 9:30a - Product, Disease Awareness, Medical Information Program*
Breakfast will be served.
Sponsored by Arbor Pharmaceuticals, Roger Kasendorf, MD

9:30a - 9:40a - Break & Exhibits

9:40a - 10:40a - Does Understanding=Analgesia? Explaining Pain Neuroscience & Physiology

UAN 0530-0000-18-156-L01-P

AANP Rx Hours 0.0

Course Description

A large body of research supports the use of pain science education--explaining pain from a neurophysiology framework--in conjunction with other treatment interventions for optimal outcomes in patients living with daily pain. What does pain science education mean and how is it delivered? This course is designed for people who wish to improve their knowledge about pain physiology, learn about updated research in this area, and develop skills in teaching people about this complex sensory experience that all humans share but very few understand. In this course, we'll review research supporting the use of neuroscience education in rehabilitation of patients living with pain. Attendees will learn how to demonstrate at least one didactic technique using a metaphor or story to explain pain to a patient. Finally, learners will be able to restate the benefits of framing pain from a nervous system perspective, rather than an anatomical one.

Kathryn A. Schopmeyer, PT, DPT, CPE

10:40a - 11:40a - Minimizing Pills and Maximizing Skills: Achieving Successful Opioid Cessation in Chronic Pain

UAN 0530-0000-18-062-L01-P

AANP Rx Hours 0.10

Course Description

Per the department of Health and Human Services, opioid related overdose deaths have increased almost 400% over the last 18 years. This shift has yielded heightened scrutiny of prescribing practices, and opioids have subsequently fallen out of favor as a first-line treatment for chronic pain. In this changing landscape of pain care, it is more important than ever for clinicians to identify treatment pathways that will maximize patient outcomes while minimizing medication load. This presentation will review current literature related to use of opioids and medical challenges associated with weaning individuals off this class of drug. The role of evidence based behavioral treatment modalities known to result in improvement in physical and emotional functioning will be discussed in detail, including their use in the context of opioid weaning. The terms dependence, abuse, tolerance, and addiction are often used interchangeably when discussing opioid medication; however, use of nomenclature in this fashion is erroneous. The differences between these words will be explained and the implications for treatment discussed. Clinical pathways that often lead to medication escalation will be identified. The role of behavioral interventions for pain treatment and the literature supporting their use will be reviewed, including data from an interdisciplinary clinical program which provides patients such education while concurrently reducing opioid medication.

Ravi Prasad, PhD

11:40a - 12:00p - Faculty Q&A

12:00p - 12:10p - Break & Exhibits

12:10p - 1:10p - Product, Disease Awareness, Medical Information Program*
Lunch will be served.
Sponsored by AstraZeneca and Daiichi Sankyo Inc., Damon Raskin, MD

1:10p - 4:20p - Extended-Release and Long-Acting Opioid Analgesics: Risk Evaluation and Mitigation Strategy (REMS)

3.0 AMA PRA Category 1TM Credits [Compliant with the FDA ER/LA Opioid REMS education requirements]

UAN 0530-9999-18-064-L01-P

AANP Rx Hours 0.5

Program Overview: Pain is a significant public health problem, affecting more than 100 million adults in the US and causing significant reductions in patients' quality of life. The use of narcotic medications for pain management has increased dramatically in the US over the past two decades. However, pain patients are often undertreated due to a variety of physician- and patient-related concerns and barriers.

In addition, despite the pain-relieving properties of opioid medications, the potential for abuse remains a concern. In response to this apprehension about opioid misuse, overdose, abuse, and addiction, the Food and Drug Administration (FDA) developed the Risk Evaluation and Mitigation Strategy (REMS) to ensure that the benefits outweigh the risks for long-acting and extended-release opioid analgesics.

The activity, Extended-Release and Long-Acting Opioid Analgesics: Risk Evaluation and Mitigation Strategy (REMS), incorporates the REMS blueprint into education that is designed to induce changes in physician knowledge, competence, and performance that will translate into improved quality of patient care and reduced pain for patients.

Target Audience: This education is intended for primary care providers and other clinicians involved in pain management, and is designed to help them recognize and balance optimal pain reduction to improve function and productivity with minimization of adverse events (e.g. abuse, addiction, and risk of workplace accidents). Additional challenges to optimal pain management include keeping up to date with the increasing volume of information on pain management, implementing changes recommended by evolving guidelines, and recognizing changes to practice needed to combat the growing rate of opioid abuse.

Jointly provided by Global Education Group and Rockpointe

This educational activity is supported by an independent educational grant from the Extended-Release/Long-Acting Opioid Analgesic REMS Program Companies. Please see for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Extended-Release/Long-Acting Opioid Analgesics REMS education requirements issued by the US Food & Drug Administration.

Bill McCarberg, MD
Martin D. Cheatle, PhD


*Not certified for credit.